Suven Life Sciences get US Patent

Suven Life Sciences has informed us that the company has secured US Patent # 7,297,711.
This is Suven’s first product patent granted in USA. The granted claims of the patent include the class of selective serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents.

According to the invention ‘711 patent disclosure, the compounds are useful in the treatment of neuro-degenarative disorders like alzheimer’s parkinson, schizophrenia and huntington’s.